Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.medcli.2017.04.029 | DOI Listing |
Med Clin (Barc)
October 2017
Unidad de Enfermedades Autoinmunes Sistémicas, Servicio de Medicina Interna, Complejo Hospitalario Universitario de Granada, Granada, España.
Med Clin (Barc)
December 1997
Servicio de Oncología Médica, Hospital Universitario San Carlos, Madrid.
Objective: To evaluate the therapeutic efficacy (in terms of overall survival [OS] and progression-free survival [PFS]) of a high-dose chemotherapy protocol including four drugs and peripheral stem cell rescue (PSCR) plus posttransplant G-CSF (filgrastim) in disseminated breast cancer patients.
Patients And Methods: Fifty-three metastatic breast cancer patients were treated with a four-drug program of high-dose chemotherapy including cyclophosphamide (6 g/m2), thiotepa (500 mg/m2), carboplatin (800-1,600 mg/m2) and mitoxantrone (20-60 mg/m2) with autologous peripheral blood progenitor cell support followed by filgrastim. Most cases (92%) had previously received conventional induction chemotherapy with anthracycline-containing combinations.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!